To examine TGF-β1 signaling in CKD versus control subjects, and the impact of apabetalone on TGF-β1 transcriptional targets, we used the upstream regulator analysis in Ingenuity Pathway Analysis (IPA) software released July 2021 to interpret plasma proteomics data. The gene discussed is TGFB1; the disease is chronic kidney disease.